This randomized, double-blind study was designed to evaluate analgesic effectiveness and side effects of two @entity1937 infusion rates in @entity1 undergoing extracorporeal shock wave lithotripsy (ESWL) for @entity1290 . We included 200 @entity1 who were administered @entity1937 either 0.05 microg x kg(-1) x @entity1009 ) (n = 100) or 0.1 microg x kg(-1) x @entity1009 ) (n = 100) plus demand bolus of 10 microg of @entity1937 via a @entity1 -controlled analgesia (PCA) device. No other sedating drugs were given. The frequencies of @entity4901 demands and deliveries were recorded. Arterial blood pressure, @entity26 saturation, and respiratory rate were recorded throughout the procedure; @entity1209 ( @entity1209 ), @entity1296 , @entity111 , @entity2146 , and @entity1576 were measured posttreatment. @entity227 ( @entity227 ) scores were taken preoperatively, directly postoperatively, and 30 min after finishing the procedure. There were no statistically significant differences in the frequency of PCA demands and delivered boluses or among perioperative @entity227 scores. The extent of @entity1209 and frequency of @entity1296 and @entity111 immediately after and @entity1296 30 min after the end of treatment were significantly reduced in the smaller dose group. We conclude that a @entity1937 regimen of 0.05 microg x kg(-1) x @entity1009 ) plus 10 microg demands is superior to 0.1 microg x kg(-1) x @entity1009 ) plus demands, as there was no difference in the @entity227 scores recorded between groups and it has a less frequent incidence of side effects in @entity1 receiving ESWL. IMPLICATIONS: @entity1937 is an appropriate analgesic choice for @entity1 undergoing extracorporeal shock wave lithotripsy (ESWL) therapy, as it has both fast onset and offset times. We studied @entity1937 as a sole drug for ESWL and have shown that an infusion rate of 0.05 microg x kg-1 x @entity1009 plus @entity1 -controlled analgesia demands of 10 microg provides adequate analgesia and has significantly less side effects than a dose of 0.1 microg x kg-1 x @entity1009 plus 10 microg demands.

XXXX as a single drug for extracorporeal shock wave lithotripsy: a comparison of infusion doses in terms of analgesic potency and side effects.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity227 :: ('MESH:D014786', 'Disease') :: ['VAS', 'Visual analog scale'] @entity1009 :: ('966', 'Gene') :: ['min-1', 'min(-1'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['PONV', 'postoperative nausea and vomiting'] @entity111 :: ('MESH:D011537', 'Disease') :: ['itching'] @entity1290 :: ('MESH:D007669', 'Disease') :: ['renal stones'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['agitation'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory depression'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity4901 :: ('CHEBI:36751', 'Chemical') :: ['PCA'] @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil', 'Remifentanil']
@entity1937 :: (MESH:C071741,Chemical) :: ['Remifentanil']
